Tiziana Life Sciences plc ("Tiziana" or the "Company") - Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today

Rhea-AI Summary

Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) announces that Chairman Gabriele Cerrone will appear on Bloomberg Television on March 29, 2021, at 1:20 PM EST. This interview will be featured on the Bloomberg Surveillance Show. Tiziana Life Sciences is a UK biotechnology firm concentrating on therapeutics for oncology and immunology, with ongoing developments such as Milciclib and Foralumab, which is a fully human anti-CD3 monoclonal antibody. The company is also advancing an anti-IL6R monoclonal antibody aimed at treating COVID-19 patients.

Positive

• Chairman Gabriele Cerrone's interview on Bloomberg could enhance visibility and investor interest.
• Ongoing development of Foralumab, a unique fully human anti-CD3 monoclonal antibody, which may have broad applications.
• Focus on anti-IL6R monoclonal antibody indicates proactive steps in addressing COVID-19.

Negative

• None.

NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that the Chairman and founder, Gabriele Cerrone, will give an interview on Bloomberg Television on Monday, 29 March 2021 at 1.20 p.m. US Eastern Standard Time (6.20 p.m. London) as part of the Bloomberg Surveillance Show.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc (TLSA)
Gabriele Cerrone, Chairman and founder
+44 (0)20 7495 2379

U.S. Investor Relations Contact:

RedChip Companies, Inc.
Dave Gentry1-800 RED-CHIP (733-2447)

Or 407-491-4498

Dave@redchip.com

407-491-4498
dave@redchip.com

FAQ

When is Gabriele Cerrone's interview on Bloomberg Television?

Gabriele Cerrone's interview is scheduled for March 29, 2021, at 1:20 PM US Eastern Standard Time.

What is Tiziana Life Sciences focused on?

Tiziana Life Sciences focuses on innovative therapeutics for oncology, inflammation, and infectious diseases.

What is the significance of Foralumab?

Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, with potential applications in various autoimmune diseases.

What treatment is Tiziana Life Sciences developing for COVID-19?

Tiziana is developing an anti-IL6R monoclonal antibody for the treatment of IL6-induced inflammation, especially in COVID-19 patients.